Athens

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Heart failure4 trials
• COPD3 trials
• Amyloidosis2 trials
• Asthma2 trials
• Chronic kidney disease2 trials
• Lung cancer2 trials
• Bronchiectasis1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Idiopathic pulmonary fibrosis1 trial
• Liver and biliary tract cancer1 trial
• and 5 more

Phase

• Phase 312 trials
• Phase 24 trials

Status

• Completed9 trials
• Active, not recruiting7 trials
• Not yet recruiting5 trials
• Recruiting5 trials

Lead sponsor

• AstraZeneca22 trials
• Alexion Pharmaceuticals, Inc.4 trials

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice

  NCT07800754· AstraZeneca· Source

• Recruiting

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

  NCT06712563· AstraZeneca· Source

• Active, not recruiting

  EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece

  NCT06724575· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Source

• Active, not recruiting

  A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

  NCT05389449· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Ovarian cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece

  NCT06185660· AstraZeneca· Source

• Completed

  Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.

  NCT06046534· AstraZeneca· Source

• Completed

  Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

  NCT05915182· AstraZeneca· Source

• Completed

  Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece

  NCT05635331· AstraZeneca· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· Phase 2· AstraZeneca· Source

• Completed

  A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.

  NCT05440656· AstraZeneca· Source

• Completed

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Completed

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· Phase 3· AstraZeneca· Source

• Completed

  HF Prevalence and Evolution of HF in DM II Patients at High Risk

  NCT04482283· AstraZeneca· Source